Gastric Cancer Risk Factors Associated With EU and CELAC Populations

Completed

• Conditions: Cancer, Gastric

• Registration Number: NCT03957031
• Lead Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Brief Summary

The study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of GC diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of GC i

Detailed Description

GC is associated to several known risk factors. Epidemiological and molecular features of GCs can vary widely. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori), Epstein Barr virus infection, dietary factors and others. These factors can influence GC outcomes. There is little knowledge regarding how these risk factors are associated with GC in CELAC and EU populations.

The primary objectives of this study are to:

1. Identify risk factors associated with GC in the CELAC and EU populations participating in this study including Argentina, Spain, Mexico, Netherlands, Chile, Portugal and Paraguay.

2. Identify clinical, demographic, and epidemiological differences among the populations participating in this study

Study Timeline

• Study First Submitted: 2019-05-17
• Study First Submitted QC: 2019-05-20
• Study First Posted: 2019-05-21
• Study Start: 2019-05-31
• Primary Completion: 2023-12-31
• Study Completion: 2023-12-31
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-08
• Last Update Posted: 2024-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exposure to a variety of potential sources of GC risk factors	3 years	The ratio of the odds of exposure vs. odds of no exposure to a variety of potential sources of GC risk factors in cases vs. controls.

Trial Locations

Locations (8)

Instituto Alexander Fleming; 🇦🇷 Buenos Aires, Argentina

Pontificia Universidad Católica de Chile; 🇨🇱 Santiago, Chile

Instituto Nacional de Cancerología; 🇲🇽 Mexico City, Mexico

VU Medical Centre; 🇳🇱 Amsterdam, Netherlands

GenPat; 🇵🇾 Asunción, Paraguay

Institute of Pathology and Immunology of University of Porto; 🇵🇹 Porto, Portugal

Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO); 🇪🇸 Barcelona, Spain

Hospital Clínico Universitario de Valencia; 🇪🇸 Valencia, Spain